Абстрактный

Short Review on Dapagliflozin

Vishnu Vardhan

Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

Отказ от ответственности: Этот реферат был переведен с помощью инструментов искусственного интеллекта и еще не прошел проверку или верификацию

Индексировано в

Google Scholar
Открыть J-ворота
ResearchBible
CiteFactor
Космос ЕСЛИ
Индекс открытых академических журналов (OAJI)
научный руководитель
Publons
Импакт-фактор Международного инновационного журнала (IIJIF)
Международный институт организованных исследований (I2OR)
Cosmos
Женевский фонд медицинского образования и исследований
Секретные лаборатории поисковых систем
Евро Паб

Посмотреть больше